Home > Press > Dr. Mark Prausnitz Joins Apogee's Medical Advisory Board
Apogee Technology, Inc. (AMEX: ATA), an emerging micro-systems and nanotechnology company that designs, develops and commercializes medical devices and sensor products, reported today that Dr. Mark Prausnitz has joined the Company's Medical Advisory Board. Dr. Prausnitz is a Professor of Chemical and Biomedical Engineering and the Emerson-Lewis Faculty Fellow at the Georgia Institute of Technology. Dr. Prausnitz's research interests concern microneedles and other microfabricated devices for drug delivery across the skin and into the eye, as well as novel uses of ultrasound and related physical phenomena to enhance and target intracellular delivery.
Dr. Mark Prausnitz Joins Apogee's Medical Advisory Board
NORWOOD, MA | Posted on January 23rd, 2007
Dr. Alexander Andrianov, Apogee's Vice President of Research and Development, said, "Dr. Prausnitz is one of the leading researchers in the area of microneedle drug delivery. His expertise covers not only the design and fabrication of microneedles, but encompasses basic questions of drug transport, insertion mechanics of microneedles in skin along with applied questions relating to drug and vaccine delivery. We are extremely excited to have him join our team to support the commercialization of our PyraDerm™ and other transdermal delivery solutions for FDA regulated and non regulated applications."
Dr. Prausnitz received the CAREER Young Investigator Award from the National Science Foundation; Young Investigator Award, Outstanding Pharmaceutical Paper Award and Outstanding Transdermal Drug Delivery Award from the Controlled Release Society; Curtis W. McGraw Research Award from the American Society for Engineering Education; and TR100 Young Innovator from Technology Review. Dr. Prausnitz has a B.S. (1988) from Stanford University and a Ph.D. (1994) from Massachusetts Institute of Technology. He has published more than 80 research articles, holds 15 issued or pending patents, consults for a number of companies, and serves as an expert witness.
About Apogee Technology, Inc.
Apogee Technology designs, develops and commercializes proprietary medical device and sensor products using its MEMS and nanotechnology for the medical, automotive, industrial and consumer markets. The Company is developing its PyraDerm™ solution for enhanced intradermal drug delivery and has introduced a family of pressure sensors under the Sensilica® brand. Apogee's goal is to provide value-added and cost-saving solutions for our customers and, in so doing, become a global leader in the sensor and medical device fields. For more information please visit our web site at: http://www.apogeemems.com .
PyraDerm™ and Sensilica® are trademarks of Apogee Technology, Inc. All other product names noted herein may be trademarks of their respective holders. Certain statements made herein that use the words "anticipate," "hope," "estimate," "project," "will," "intend," "plan," "expect," "believe" and similar expressions are intended to identify forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements involve known and unknown risks and uncertainties, which could cause the actual results, performance or achievements of the Company to be materially different from those that may be expressed or implied. Please refer to the company's risk factors as set forth in the Company's filings with the Securities and Exchange Commission, including its reports on Forms 10-KSB and 10-QSB.
For more information, please click here
Apogee Investor Contact:
Premier Funding & Financial Marketing
Copyright © Market Wire
If you have a comment, please Contact
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
NYU Researchers Break Nano Barrier to Engineer the First Protein Microfiber October 23rd, 2014
Iranian Scientists Apply Nanotechnology to Produce Surgery Suture October 23rd, 2014
RF Heating of Magnetic Nanoparticles Improves the Thawing of Cryopreserved Biomaterials October 23rd, 2014
Sopping up proteins with thermosponges: Researchers develop novel nanoparticle platform that proves effective in delivering protein-based drugs October 22nd, 2014
Haydale Secures Exclusive Development and Supply Agreement with Tantec A/S: New reactors to be built and commissioned by Tantec A/S represent another step forward towards the commercialisation of graphene October 24th, 2014
QuantumWise guides the semiconductor industry towards the atomic scale October 24th, 2014
Advancing thin film research with nanostructured AZO: Innovnano’s unique and cost-effective AZO sputtering targets for the production of transparent conducting oxides October 23rd, 2014
Strengthening thin-film bonds with ultrafast data collection October 23rd, 2014
First Canada Excellence Research Chair gets $10 million from the federal government for oilsands research at the University of Calgary: Federal government announces prestigious research chair to study improving oil production efficiency October 19th, 2014
VDMA photonics steering committee with new members stronger than ever October 14th, 2014
Agar Scientific appoints Paul Balaş as new Technical Sales Manager October 3rd, 2014
PEN Inc. Chairman Scott Rickert Announces Company Vision, Product Priorities and Management Team: Webcast Highlights the Launch of PEN October 3rd, 2014
Iran-Made Respiratory Nano Masks Provided to Hajj Pilgrims October 23rd, 2014
Japanese gold leaf artists worked on a nano-scale: Study demonstrates X-ray fluorescence spectroscopy is a non-destructive way to date artwork July 3rd, 2014
Harry Potter-style invisibility cloaks: A real possibility next Christmas? Forget socks and shaving foam, the big kids of tomorrow want an invisible cloak for Christmas December 19th, 2013
Chicago Awareness Organization First Not-for-Profit to Sponsor Dog Training to Detect Ovarian Cancer Odorants December 12th, 2013